Chuikyo Members Open to Post-Launch Premiums for Add’l Indications, but Call for Careful Application

Members of a key reimbursement policy panel on September 11 showed their understanding for an industry proposal calling for the creation of post-launch premiums for additional indications under the next drug pricing reform in April 2020, but with a caveat...read more